Participants voluntarily agree to participate and sign the informed consent form.
Male, aged ≥18 years.
Eastern Cooperative Oncology Group (ECOG) performance status score of 0-1.
Life expectancy ≥ 3 months.
Histologically or cytologically confirmed adenocarcinoma of the prostate without evidence of neuroendocrine carcinoma or small cell carcinoma features.
Confirmed metastatic Castration-Resistant Prostate Cancer (mCRPC).
Failed or are intolerant to standard therapies
Adequate function of major organs as defined by the protocol.
Agreement to use effective contraception during the study (except for subjects who have undergone bilateral orchiectomy).
Prior to the first use of the investigational drug, recovery from all reversible adverse events (AEs) related to prior anticancer treatments
You may not be if
Previously treated with drugs targeting CD3 or CD2.
Significant Cardiovascular Diseases
Active, Uncontrolled Infections
Immunosuppressive Treatment before the first dose of the investigational drug
History of Other Malignancies within 5 years prior to the first dose of the investigational drug
Moderate to Severe Pulmonary Diseases significantly affecting lung function,
Current Hepatic Encephalopathy, Hepatorenal Syndrome, or Cirrhosis classified as Child-Pugh B or worse.
Allergy to the Investigational Drug or its Components.
Any Condition deemed by the investigator to increase study-related risks, interfere with the interpretation of study results, or otherwise render the participant unsuitable for inclusion.
Clareo Health | QLF4113 in Participants With Metastatic Prostate Cancer
